U.S. Physical Therapy (USPH) 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 07, 2014
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'U S PHYSICAL THERAPY INC /NV	'
Entity Central Index Key	'0000885978	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	12,236,099
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'

CONSOLIDATED_BALANCE_SHEETS_un

CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$12,934	$12,898
Patient accounts receivable, less allowance for doubtful accounts of $1,713 and $1,430, respectively	34,286	30,820
Accounts receivable - other, less allowance for doubtful accounts of $198 and $198, respectively	1,924	1,844
Other current assets	2,703	4,098
Total current assets	51,847	49,660
Fixed assets:	'	'
Furniture and equipment	41,310	38,965
Leasehold improvements	22,065	21,891
Fixed assets, gross	63,375	60,856
Less accumulated depreciation and amortization	47,517	45,896
Fixed assets, net	15,858	14,960
Goodwill	156,207	143,955
Other intangible assets, net	15,727	14,479
Other assets	1,141	1,081
Total assets	240,780	224,135
Current liabilities:	'	'
Accounts payable - trade	1,835	1,722
Accrued expenses	20,112	20,625
Current portion of notes payable	850	825
Total current liabilities	22,797	23,172
Notes payable	450	650
Revolving line of credit	45,000	40,000
Deferred rent	1,095	996
Other long-term liabilities	6,053	4,196
Total liabilities	75,395	69,014
Commitments and contingencies	'	'
Redeemable non-controlling interests	1,086	4,104
U. S. Physical Therapy, Inc. shareholders' equity:	'	'
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $.01 par value, 20,000,000 shares authorized, 14,450,836 and 14,315,882 shares issued, respectively	145	143
Additional paid-in capital	41,306	40,569
Retained earnings	126,934	119,206
Treasury stock at cost, 2,214,737 shares	-31,628	-31,628
Total U. S. Physical Therapy, Inc. shareholders' equity	136,757	128,290
Non-controlling interests	27,542	22,727
Total equity	164,299	151,017
Total liabilities and stockholders' equity	$240,780	$224,135

CONSOLIDATED_BALANCE_SHEETS_un1

CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Allowance for doubtful accounts, patient accounts receivable	$1,713	$1,430
Allowance for doubtful accounts, accounts receivable - other	$198	$198
U. S. Physical Therapy, Inc. shareholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	500,000	500,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	14,450,836	14,315,882
Treasury stock (in shares)	2,214,737	2,214,737

CONSOLIDATED_STATEMENTS_OF_NET

CONSOLIDATED STATEMENTS OF NET INCOME (unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
CONSOLIDATED STATEMENTS OF NET INCOME (unaudited) [Abstract]	'	'	'	'
Net patient revenues	$76,470	$65,227	$144,867	$126,659
Other revenues	1,731	1,642	3,101	2,966
Net revenues	78,201	66,869	147,968	129,625
Clinic operating costs:	'	'	'	'
Salaries and related costs	40,109	35,526	78,051	69,585
Rent, clinic supplies, contract labor and other	15,205	12,550	29,421	25,284
Provision for doubtful accounts	1,054	1,198	2,004	2,295
Closure costs	-2	8	11	26
Total clinic operating costs	56,366	49,282	109,487	97,190
Gross margin	21,835	17,587	38,481	32,435
Corporate office costs	7,614	6,528	14,746	12,941
Operating income from continuing operations	14,221	11,059	23,735	19,494
Interest and other income, net	0	1	1	3
Interest expense	-332	-130	-585	-265
Income before taxes from continuing operations	13,889	10,930	23,151	19,232
Provision for income taxes	4,469	3,288	7,408	5,781
Net income from continuing operations including non-controlling interests	9,420	7,642	15,743	13,451
Discontinued operations, net of tax	0	-268	0	-468
Net income including non-controlling interests	9,420	7,374	15,743	12,983
Less: net income attributable to non-controlling interests	-2,988	-2,460	-5,083	-4,348
Net income attributable to common shareholders	6,432	4,914	10,660	8,635
Basic earnings per share attributable to common shareholders:	'	'	'	'
From continuing operations (in dollars per share)	$0.53	$0.42	$0.88	$0.74
Revaluation of redeemable non-controlling interests, net of tax (in dollars per share)	($0.01)	$0	($0.09)	$0
From discontinued operations (in dollars per share)	$0	($0.01)	$0	($0.02)
Basic (in dollars per share)	$0.52	$0.41	$0.79	$0.72
Diluted earnings per share attributable to common shareholders:	'	'	'	'
From continuing operations (in dollars per share)	$0.53	$0.42	$0.87	$0.74
Revaluation of redeemable non-controlling interests, net of tax (in dollars per share)	($0.01)	$0	($0.09)	$0
From discontinued operations (in dollars per share)	$0	($0.01)	$0	($0.02)
Diluted (in dollars per share)	$0.52	$0.41	$0.78	$0.72
Shares used in computation:	'	'	'	'
Basic (in shares)	12,224	12,089	12,177	12,022
Diluted (in shares)	12,226	12,110	12,184	12,044
Dividends declared per common share (in dollars per share)	$0.12	$0.10	$0.24	$0.20
Earnings attributable to common shareholders:	'	'	'	'
From continuing operations	6,432	5,079	10,660	8,930
From discontinued operations	0	-165	0	-295
Net income attributable to common shareholders	$6,432	$4,914	$10,660	$8,635

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
OPERATING ACTIVITIES	'	'
Net income including non-controlling interests	$15,743	$12,983
Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities:	'	'
Depreciation and amortization	2,825	2,730
Provision for doubtful accounts	2,004	2,282
Equity-based awards compensation expense	1,593	1,370
Loss on sale of business and sale or abandonment of assets, net	34	84
Excess tax benefit from exercise of stock options	-215	0
Deferred income tax	2,422	-796
Other	0	33
Changes in operating assets and liabilities:	'	'
Increase in patient accounts receivable	-4,442	-2,542
(Increase) decrease in accounts receivable - other	-80	4
Decrease in other assets	1,540	3,867
(Decrease) increase in accounts payable and accrued expenses	-774	682
Increase in other liabilities	404	19
Net cash provided by operating activities	21,054	20,716
INVESTING ACTIVITIES	'	'
Purchase of fixed assets	-2,132	-2,394
Purchase of businesses, net of cash acquired	-10,750	-9,998
Acquisitions of non-controlling interests	-4,945	-1,064
Proceeds on sale of business and fixed assets, net	38	15
Net cash used in investing activities	-17,789	-13,441
FINANCING ACTIVITIES	'	'
Distributions to non-controlling interests	-4,982	-4,410
Cash dividends to shareholders	-2,932	-2,418
Proceeds from revolving line of credit	77,000	62,550
Payments on revolving line of credit	-72,000	-64,200
Payment of notes payable	-575	-234
Excess tax benefit from stock options exercised	215	33
Other	45	20
Net cash used in financing activities	-3,229	-8,659
Net increase in cash	36	-1,384
Cash - beginning of period	12,898	11,671
Cash - end of period	12,934	10,287
Cash paid during the period for:	'	'
Income taxes	3,235	1,999
Interest	657	237
Non-cash investing and financing transactions during the period:	'	'
Purchase of business - seller financing portion	400	800
Revaluation of redeemable non-controlling interests	$1,841	$0

CONSOLIDATED_STATEMENT_OF_SHAR

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (unaudited) (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total Shareholders' Equity [Member]	Non-controlling Interests [Member]	Total
In Thousands, unless otherwise specified
Beginning Balance at Dec. 31, 2013	$143	$40,569	$119,206	($31,628)	$128,290	$22,727	$151,017
Beginning Balance (in shares) at Dec. 31, 2013	14,316	'	'	-2,215	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'
Issuance of restricted stock, net of cancellations	1	0	0	0	1	0	1
Issuance of restricted stock, net of cancellations (in shares)	118	'	'	0	'	'	'
Proceeds from exercise of stock options	1	43	0	0	44	0	44
Proceeds from exercise of stock options (in shares)	17	'	'	0	'	'	'
Compensation expense - restricted stock	0	1,593	0	0	1,593	0	1,593
Purchase of business	0	0	0	0	0	4,725	4,725
Excess tax benefit of equity grants	0	215	0	0	215	0	215
Revaluation of redeemable non-controlling interests, net of tax	0	-1,086	0	0	-1,086	0	-1,086
Acquisition of non-controlling interests	0	-28	0	0	-28	-11	-39
Dividends payable to shareholders	0	0	-2,932	0	-2,932	0	-2,932
Distributions to non-controlling interest partners	0	0	0	0	0	-4,982	-4,982
Net income	0	0	10,660	0	10,660	5,083	15,743
Ending Balance at Jun. 30, 2014	$145	$41,306	$126,934	($31,628)	$136,757	$27,542	$164,299
Ending Balance (in shares) at Jun. 30, 2014	14,451	'	'	-2,215	'	'	'

BASIS_OF_PRESENTATION_AND_SIGN

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2014
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	'
	1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
	The consolidated financial statements include the accounts of U.S. Physical Therapy, Inc. and its subsidiaries (the “Company”). All significant intercompany transactions and balances have been eliminated. The Company primarily operates through subsidiary clinic partnerships, in which the Company generally owns a 1% general partnership interest and a 64% limited partnership interest. The managing therapist of each clinic owns, directly or indirectly, the remaining limited partnership interest in the majority of the clinics (hereinafter referred to as “Clinic Partnership”). To a lesser extent, the Company operates some clinics, through wholly-owned subsidiaries, under profit sharing arrangements with therapists (hereinafter referred to as “Wholly-Owned Facilities”).
	The Company continues to seek to attract physical and occupational therapists who have established relationships with patients and physicians by offering therapists a competitive salary and a share of the profits of the clinic operated by that therapist. The Company has developed satellite clinic facilities of existing clinics, with the result that many Clinic Partnerships and Wholly-Owned Facilities operate more than one clinic location. In addition, the Company has acquired a controlling interest in a number of clinics through acquisitions.
	During the first six months of 2014 and the year ended 2013, the Company acquired the following clinic groups:
			% Interest	Number of
	Acquisition	Date	Acquired	Clinics
		2014
	April 2014 Acquisition	30-Apr	70%	13
		2013
	February 2013 Acquisition	28-Feb	72%	9
	April 2013 Acquisition	30-Apr	50%	5
	May 2013 Acquisition	24-May	80%	5
	December 9, 2013 Acquisition	9-Dec	60%	12
	December 13, 2013 Acquisition	13-Dec	90%	11
	In addition to the clinic groups noted in the table above, during the six months ended June 30, 2014, the Company acquired two individual clinics in separate transactions.  One of the acquired clinics will operate as a satellite of one of the Company’s partnerships and the other will be consolidated into an existing clinic.  In 2013, the Company, through three of its subsidiaries, acquired three individual physical therapy clinics in separate transactions.
	As of June 30, 2014, the Company operated 486 clinics in 43 states.
	The results of operations of the acquired clinics have been included in the Company’s consolidated financial statements since the date of their respective acquisition.
	The Company intends to continue to focus on pursuing additional acquisition opportunities, developing new clinics and opening satellite clinics.
	The accompanying unaudited consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions for Form 10-Q. However, the statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. Management believes this report contains all necessary adjustments (consisting only of normal recurring adjustments) to present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. For further information regarding the Company’s accounting policies, please read the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	The Company believes, and the Chief Executive Officer, Chief Financial Officer and Corporate Controller have certified, that the financial statements included in this report present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented.
	Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results the Company expects for the entire year. Please also review the Risk Factors section included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	Clinic Partnerships
	For Clinic Partnerships, the earnings and liabilities attributable to the non-controlling interests, typically owned by the managing therapist, directly or indirectly, are recorded within the balance sheets and income statements as non-controlling interests.
	Wholly-Owned Facilities
	For Wholly-Owned Facilities with profit sharing arrangements, an appropriate accrual is recorded for the amount of profit sharing due to the profit sharing therapists. The amount is expensed as compensation and included in clinic operating costs – salaries and related costs. The respective liability is included in current liabilities – accrued expenses on the balance sheet.
	Significant Accounting Policies
	Long-Lived Assets
	Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets. Estimated useful lives for furniture and equipment range from three to eight years and for software purchased from three to seven years. Leasehold improvements are amortized over the shorter of the lease term or estimated useful lives of the assets, which is generally three to five years.
	Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of
	The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
	Goodwill
	Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital.
	The fair value of goodwill and other intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining our reporting units when performing our annual goodwill impairment test.
	An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two methods: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a put price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2013, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluations in the third quarter of 2013 and 2012 did not yield any impairment charge. During the six months ended June 30, 2014, the Company did not identify any triggering events occurring after the testing date that would impact the impairment testing results obtained.
	Non-controlling interests
	The Company recognizes non-controlling interests as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the income statement. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling interest on the deconsolidation date.
	When the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.
	The non-controlling interests that are reflected as redeemable non-controlling interests in the consolidated financial statements consist of those owners who have certain redemption rights that are currently exercisable, and that, if exercised, require that the Company purchase the non-controlling interest of the particular limited partner.  The redeemable non-controlling interests are adjusted to the fair value in the reporting period in which the Company deems it probable that the limited partner will assert the redemption rights and will be adjusted each reporting period thereafter.  The adjustments are charged to additional paid-in capital and are not reflected in the statement of net income.  Although the adjustments are not reflected in the statement of net income, current accounting rules require that the Company reflect the charge in the earnings per share calculation.
	Typically, for acquisitions, the Company agrees to purchase the individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.
	Revenue Recognition
	Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience.
	The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in clinic operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.
	Medicare Reimbursement
	The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (“MPFS”). The MPFS rates are automatically updated annually based on a formula, called the sustainable growth rate (“SGR”) formula. The use of the SGR formula would have resulted in calculated automatic reductions in rates in every year since 2002; however, for each year through June 30, 2014, Centers for Medicare & Medicaid Services (“CMS”) or Congress has taken action to prevent the implementation of SGR formula reductions. The Bipartisan Budget Act of 2013 froze the Medicare physician fee schedule rates at 2013 levels through June 30, 2014, averting a scheduled 20.1% cut in the MPFS as a result of the SGR formula that would have taken effect on January 1, 2014. The Protecting Access to Medicare Act of 2014 temporarily blocks this reduction through March 31, 2015 and replaces it with a 0.5% payment increase for services provided through December 31, 2014 and a 0% payment update from January 1, 2015 through March 31, 2015. Automatic reductions in the Medicare physician fee schedule payment rates will commence on April 1, 2015, unless Congress again takes legislative action to prevent the SGR formula reductions from going into effect.
	The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap.  On April 1, 2013, a 2% reduction to Medicare payments was implemented.
	As a result of the Balanced Budget Act of 1997, the formula for determining the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary (i.e., the “Therapy Cap” or “Limit”) was established. Based on the statutory definitions which constrained how the Therapy Cap would be applied, there is one Limit for Physical Therapy and Speech Language Pathology Services combined, and one Limit for Occupational Therapy. Since January 1, 2014, the annual Limit on outpatient therapy services is $1,920 for Physical and Speech Language Pathology Services combined and $1,920 for Occupational Therapy Services.  Historically, these Therapy Caps applied to outpatient therapy services provided in all settings, except for services provided in departments of hospitals. However, the Protecting Access to Medicare Act of 2014, and prior legislation, extended the annual limits on therapy expenses and the manual medical review thresholds to services furnished in hospital outpatient department settings through March 31, 2015. The application of annual limits will no longer apply to hospital outpatient department settings commencing as of March 31, 2015 unless Congress extends it.
	In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual Limit for therapy expenses for therapy services above the annual Limit.  Therapy services above the annual Limit that are medically necessary satisfy an exception to the annual Limit and such claims are payable by the Medicare program. The Protecting Access to Medicare Act of 2014 extended the exceptions process for outpatient therapy caps through March 31, 2015.   Unless Congress extends the exceptions process further, the therapy caps will apply to all outpatient therapy services beginning April 1, 2015, except those services furnished and billed by outpatient hospital departments.  For any claim above the annual Limit, the claim must contain a modifier indicating that the services are medically necessary and justified by appropriate documentation in the medical record.
	Furthermore, under the Middle Class Tax Relief and Job Creation Act of 2012 (“MCTRA”), since October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review to determine whether applicable payment criteria are satisfied. The $3,700 threshold is applied to Physical Therapy and Speech Language Pathology Services; a separate $3,700 threshold is applied to the Occupational Therapy. The Protecting Acces to Medicare Act of 2014 extended through March 31, 2015 the requirement that Medicare perform manual medical review of therapy services beyond the $3,700 threshold.
	CMS adopted a multiple procedure payment reduction (“MPPR”) for therapy services in the final update to the MPFS for calendar year 2011. During 2011, the MPPR applied to all outpatient therapy services paid under Medicare Part B — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (“RVU”) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. In 2011 and 2012, the practice expense component for the second and subsequent therapy service furnished during the same day for the same patient was reduced by 20% in office and other non-institutional settings and by 25% in institutional settings. The American Taxpayer Relief Act of 2012 increased the payment reduction of the practice expense component to 50%, on subsequent therapy procedures in either setting, effective April 1, 2013. In addition, the Middle Class Tax Relief and Job Creation Act of 2012 (“MCTRA”) directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. Since July 1, 2013, therapists have been required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge. Since July 1, 2013, CMS has rejected claims if the required data is not included in the claim.
	The Physician Quality Reporting System, or "PQRS," is a CMS reporting program that uses a combination of incentive payments and payment reductions to promote reporting of quality information by "eligible professionals." Although physical therapists, occupational therapists and qualified speech-language therapists are generally able to participate in the PQRS program, therapy professionals for whose services we bill through our rehab agencies cannot participate because the Medicare claims processing systems currently cannot accommodate institutional providers such as rehab agencies. Eligible professionals, such as those of our therapy professionals for whose services we bill using their individual Medicare provider numbers, who do not satisfactorily report data on quality measures will be subject to a 2% reduction in their Medicare payment in 2016.
	Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. The Company believes that it is in compliance in all material respects with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements as of June 30, 2014. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program.
	Management Contract Revenues
	Management contract revenues are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company’s employees, are recorded when incurred. Management contract revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income.
	Contractual Allowances
	Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements for such services by both insurance companies and government sponsored healthcare programs. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company’s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow it to provide the necessary detail and accuracy with its collectibility estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company’s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company’s billing systems may not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues, and hence, its contractual allowance reserves. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, the difference between net revenues and corresponding cash collections has historically generally reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent period’s contractual write-offs on a payor basis shows a less than 1% difference between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at June 30, 2014.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.
	The Company recognizes accrued interest expense and penalties associated with unrecognized tax benefits as income tax expense. The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the three and six months ended June 30, 2014 and 2013.
	On September 13, 2013, the U.S. Treasury Department and the I.R.S. issued final regulations that address costs incurred in acquiring, producing, or improving tangible property (the “Tangible Property Regulations”).  The Tangible Property Regulations are generally effective for tax years beginning on or after January 1, 2014, and may be adopted in earlier years.  The Company adopted the tax treatment of expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property as of January 1, 2014.  Historically, the Company has treated the expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property similar for tax and book.  Management does not anticipate the impact of these changes to be material to the Company’s consolidated financial statements.
	Fair Value of Financial Instruments
	The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount of the Company’s revolving line of credit approximates its fair value. The interest rate on the revolving line of credit, which is tied to the Eurodollar Rate, is set at various short-term intervals as detailed in the Credit Agreement (as defined in Note 9).
	Segment Reporting
Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.
Use of Estimates
In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.
Self-Insurance Program
The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through June 30, 2014.
Restricted Stock
Restricted stock issued to employees and directors is subject to certain conditions, including continued employment or continued service on our Board of Directors (the “Board”), respectively. The transfer restrictions for shares granted to directors lapse in four equal quarterly installments and those to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the service period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.
Reclassifications
Prior period amounts have been reclassified to conform to current period presentation due to discontinued operations recognized in 2013.
Recently Issued Accounting Guidance
In April 2014, the Financial Accounting Standards Board issued changes to reporting discontinued operations and disclosures of disposals of components of an entity. These changes require a disposal of a component to meet a higher threshold in order to be reported as a discontinued operation in an entity's financial statements. The threshold is defined as a strategic shift that has, or will have, a major effect on an entity's operations and financial results such as a disposal of a major geographical area or a major line of business. Additionally, the following two criteria have been removed from consideration of whether a component meets the requirements for discontinued operations presentation: (i) the operations and cash flows of a disposal component have been or will be eliminated from the ongoing operations of an entity as a result of the disposal transaction, and (ii) an entity will not have any significant continuing involvement in the operations of the disposal component after the disposal transaction. Furthermore, equity method investments now may qualify for discontinued operations presentation. These changes also require expanded disclosures for all disposals of components of an entity, whether or not the threshold for reporting as a discontinued operation is met, related to profit or loss information and/or asset and liability information of the component. These changes become effective for the Company on January 1, 2015. Management has determined that the adoption of these changes will not have an immediate impact on the Consolidated Financial Statements.

EARNINGS_PER_SHARE

EARNINGS PER SHARE	6 Months Ended
	Jun. 30, 2014
EARNINGS PER SHARE [Abstract]	'
EARNINGS PER SHARE	'
	2. EARNINGS PER SHARE
	The computations of basic and diluted earnings per share for the Company are as follows (in thousands, except per share data):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Earnings attributable to common shareholders:
	From continuing operations	$	6,432		$	5,079		$	10,660		$	8,930
	From discontinued operations		-			(165	)		-			(295	)
			6,432			4,914			10,660			8,635
	Revaluation of redeemable non-controlling interests, net of tax		(119	)		-			(1,086	)		-
		$	6,313		$	4,914		$	9,574		$	8,635
	Diluted earnings per share attributable to common shareholders:
	From continuing operations	$	0.53		$	0.42		$	0.87		$	0.74
	Basic earnings per share attributable to common shareholders:
	From continuing operations	$	0.53		$	0.42		$	0.88		$	0.74
	Charges to additional-paid-in-capital  - revaluation of redeemable non-controlling interests, net of tax		(0.01	)		-			(0.09	)		-
	From discontinued operations		-			(0.01	)		-			(0.02	)
	Basic	$	0.52		$	0.41		$	0.79		$	0.72
	Diluted earnings per share attributable to common shareholders:
	From continuing operations	$	0.53		$	0.42		$	0.87		$	0.74
	Charges to additional-paid-in-capital - revaluation of redeemable non-controlling interests, net of tax		(0.01	)		-			(0.09	)		-
	From discontinued operations		-			(0.01	)		-			(0.02	)
	Diluted	$	0.52		$	0.41		$	0.78		$	0.72
	Shares used in computation:
	Basic earnings per share - weighted-average shares		12,224			12,089			12,177			12,022
	Effect of dilutive securities - stock options		2			21			7			22
	Denominator for diluted earnings per share - adjusted weighted-average shares		12,226			12,110			12,184			12,044
	All options to purchase shares were included in the diluted earnings per share calculation for the six months ended June 30, 2014 and 2013 as the average market prices of the common stock was above the exercise prices. The Company’s restricted stock issued is included in basic and diluted shares for the earnings per share computation from the date of grant.
	The charges to additional paid-in capital – revaluation of redeemable non-controlling interests, net of tax represent the increase in the fair value of the redeemable non-controlling interest that were deemed probable that the owners would assert the redemption rights. See Note 1 – Basis of Presentation and Significant Accounting Policies – Non-controlling Interests.

ACQUISITIONS_OF_BUSINESSES

ACQUISITIONS OF BUSINESSES	6 Months Ended
	Jun. 30, 2014
ACQUISITIONS OF BUSINESSES [Abstract]	'
ACQUISITIONS OF BUSINESSES	'
	3. ACQUISITIONS OF BUSINESSES
	On April 30, 2014, the Company acquired a 70% interest in a 13-clinic physical therapy practice.  The purchase price for the 70% interest was $10,625,000 in cash and $400,000 in a seller note, that is payable in two principal installments totaling $200,000 each, plus accrued interest, in April 2015 and 2016. In addition, during the six months ended June 30, 2014, the Company acquired two individual clinic practices for an aggregate of $125,000 in cash.
	The purchase prices for the 2014 acquisitions have been preliminarily allocated as follows (in thousands):
	Cash paid, net of cash acquired	$	10,750
	Seller notes		400
	Total consideration	$	11,150
	Estimated fair value of net tangible assets acquired:
	Total current assets	$	1,203
	Total non-current assets		1,200
	Total liabilities		(374	)
	Net tangible assets acquired		2,029
	Referral relationships		-
	Non-competition agreements		-
	Tradename		-
	Goodwill		13,846
	Fair value of non-controlling interest		(4,725	)
		$	11,150
	During 2013, the Company completed the following multi-clinic acquisitions of physical therapy practices:
				% Interest				Number of
	Acquisition	Date		Acquired				Clinics
	February 2013 Acquisition	28-Feb			72%			9
	April 2013 Acquisition	30-Apr			50%			5
	May 2013 Acquisition	24-May			80%			5
	December 9, 2013 Acquisition	9-Dec			60%			12
	December 13, 2013 Acquisition	13-Dec			90%			11
	In addition to the five multi-clinic acquisitions detailed above, in 2013, the Company acquired three individual clinics in separate transactions.
	The purchase price for the 72% interest in the February 2013 Acquisition was $4.3 million in cash and $400,000 in a seller note, that is payable in two principal installments totaling $200,000 each, plus accrued interest, in February 2014 and 2015. The purchase price for the 50% interest in the April 2013 Acquisition was $2.4 million in cash and $200,000 in a seller note, that is payable in two principal installments totaling $100,000 each, plus accrued interest, in April of 2014 and 2015. The purchase price for the 80% interest in the May 2013 Acquisition was $3.6 million in cash and $200,000 in a seller note, that is payable in two principal installments totaling $100,000 each, plus accrued interest, in May of 2014 and 2015. The purchase price for the 60% interest in the December 9, 2013 Acquisition was $1.7 million in cash. The purchase price for the 90% interest in the December 13, 2013 Acquisition was $35.5 million in cash and $500,000 in a seller note, that is payable in two principal installments totaling $250,000 each, plus accrued interest, in December 2014 and 2015.
	On February 1, 2013, through a subsidiary, the Company acquired a 100% interest in a clinic for $5,000. On June 1, 2013, the Company acquired a 100% interest in a clinic for $95,000. On September 16, 2013, the Company acquired a 100% interest in a clinic for $130,000.
	The purchase prices for the 2013 acquisitions have been preliminarily allocated as follows (in thousands):
	Cash paid, net of cash acquired	$	46,628
	Seller notes		1,300
	Total consideration	$	47,928
	Estimated fair value of net tangible assets acquired:
	Total current assets	$	3,756
	Total non-current assets		2,283
	Total liabilities		(1,082	)
	Net tangible assets acquired		4,957
	Referral relationships		940
	Non-competition agreements		400
	Tradename		1,500
	Goodwill		50,672
	Fair value of non-controlling interest		(10,541	)
		$	47,928
	The consideration for each transaction was agreed upon through arm’s length negotiations. Funding for the cash portion of the purchase price for the 2014 and 2013 acquisitions was derived from proceeds under the Credit Agreement.
	The results of operations of these acquisitions have been included in the Company’s consolidated financial statements since acquired.
	For the 2014 acquistions and the two acquisitions which occurred in December, 2013, the purchase price plus the fair value of the non-controlling interest for those two acquisitions was allocated to the fair value of the assets acquired and liabilities assumed based on the preliminary estimates of the fair values at the acquisition date, with the amount exceeding the estimated fair values being recorded as goodwill. The Company is in the process of completing its formal valuation analysis to identify and determine the fair value of tangible and identifiable intangible assets acquired and the liabilities assumed. Thus, the final allocation of the purchase price may differ from the preliminary estimates used based on additional information obtained. Changes in the estimated valuation of the tangible and intangible assets acquired and the completion by the Company of the identification of any unrecorded pre-acquisition contingencies, where the liability is probable and the amount can be reasonably estimated, will likely result in adjustments to goodwill.
	Except for the December 13, 2013 Acquisition, unaudited proforma consolidated financial information for acquisitions occurring in 2013 have not been included as the results were not material to current operations.
	Unaudited proforma net revenue and net income from continuing operations for the Company as if the December 13, 2013 Acquisition occurred as of January 1, 2013 is as follows (in thousands, except per share data):
		Three Months				Six Months
		Ended				Ended
		30-Jun-13				30-Jun-13
	Net revenues	$	69,563			$	135,024
	Net income attributable to common shareholders from continuing operations	$	5,717			$	9,750
	Earnings per share:
	Basic - net income attributable to common shareholders from continuing operations	$	0.47			$	0.81
	Diluted - net income attributable to common shareholders from continuing operations	$	0.47			$	0.81
	Shares used in computation:
	Basic - net income attributable to common shareholders from continuing operations		12,089				12,022
	Diluted - net income attributable to common shareholders from continuing operations		12,110				12,044

ACQUISITIONS_AND_REVALUATIONS_

ACQUISITIONS AND REVALUATIONS OF NON-CONTROLLING INTERESTS	6 Months Ended
	Jun. 30, 2014
ACQUISITIONS AND REVALUATIONS OF NON-CONTROLLING INTERESTS [Abstract]	'
ACQUISITIONS AND REVALUATIONS OF NON-CONTROLLING INTERESTS	'
	4. ACQUISITIONS AND REVALUATIONS OF NON-CONTROLLING INTERESTS
	In four separate transactions during the six months ended June 30, 2014, the Company purchased interests in two partnerships which were previously classified as redeemable non-controlling interest. The interests in the partnerships purchased ranged from 10.0% to 35.0%. The aggregate of the purchase prices paid was $4.9 million, which included $3.0 million of net book value. The remaining purchase price of $1.9 million, less future tax benefits of $0.8 million, was recognized as an adjustment to additional paid-in capital.
	For the six months ended June 30, 2014, the following table details the changes in the carrying amount of redeemable non-controlling interest:
		Six Months
		Ended
		30-Jun-14
	Beginning balance	$	4,104
	Increase due to revaluation and operating results of redeemable non-controlling interests		1,869
	Purchases of redeemable non-controlling interests		(4,887	)
	Ending balance	$	1,086
	The non-controlling interests that are reflected as redeemable non-controlling interests in the consolidated financial statements consist of those owners who have certain redemption rights that are currently exercisable, and that, if exercised, require that the Company purchase the non-controlling interest of those owners.  The redeemable non-controlling interests are adjusted to the fair value in the reporting period in which the Company deems it probable that the limited partner will assert the redemption rights and it will be adjusted each reporting period thereafter.  The adjustments are charged to additional paid-in capital and are not reflected in the statement of net income.  Although the adjustments are not reflected in the statement of net income, current accounting rules require that the Company reflect the charge in the earnings per share calculation.

DISCONTINUED_OPERATIONS

DISCONTINUED OPERATIONS	6 Months Ended
	Jun. 30, 2014
DISCONTINUED OPERATIONS [Abstract]	'
DISCONTINUED OPERATIONS	'
	5. DISCONTINUED OPERATIONS
	On September 30, 2013, the Company sold the remainder of its physician services business. Previously, the Company closed its two physician services facilities – one in August 2013 and the other in December 2012. As previously disclosed in the Company’s public filings, the physician services business incurred negative gross margins in 2012 and through the first nine months of 2013. The results of operations and the loss on the sale of the physician services business have been reclassified to discontinued operations for all periods presented.
	The following table details the losses from discontinued operations reported for the physician services business:
		Three Months			Six Months
		Ended			Ended
		30-Jun-13			30-Jun-13
	Net revenues	$	355		$	696
	Operating costs		636			1,168
	Gross margin		(281	)		(472	)
	Direct general and administrative expenses less proceeds		94			187
			(375	)		(659	)
	Tax benefit		107			191
	Loss from discontinued operations	$	(268	)	$	(468	)
	The cash flow impact of the sale and closures is deemed immaterial for the consolidated statements of cash flows.

GOODWILL

GOODWILL	6 Months Ended
	Jun. 30, 2014
GOODWILL [Abstract]	'
GOODWILL	'
	6. GOODWILL
	The changes in the carrying amount of goodwill consisted of the following (in thousands):
		Six Months
		Ended
		30-Jun-14
	Beginning balance	$	143,955
	Goodwill acquired during the period		13,846
	Goodwill allocated to specific assets for business acquired in first six months of 2013		(1,680	)
	Goodwill adjustments for purchase price allocation of businesses acquired		86
	Ending balance	$	156,207

INTANGIBLE_ASSETS_NET

INTANGIBLE ASSETS, NET	6 Months Ended
	Jun. 30, 2014
INTANGIBLE ASSETS, NET [Abstract]	'
INTANGIBLE ASSETS, NET	'
	7. INTANGIBLE ASSETS, NET
	Intangible assets, net as of June 30, 2014 and December 31, 2013 consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Tradenames	$	10,714		$	9,814
	Referral relationships, net of accumulated amortization of $1,865 and $1,582, respectively		4,216			3,959
	Non-competition agreements, net of accumulated amortization of $2,099 and $1,950, respectively		797			706
		$	15,727		$	14,479
	Tradenames, referral relationships and non-competition agreements are related to the businesses acquired. The value assigned to tradenames has an indefinite life and is tested at least annually for impairment in conjunction with the Company’s annual goodwill impairment test. The value assigned to referral relationships is being amortized over their respective estimated useful lives which range from six to 16 years. Non-competition agreements are amortized over the respective term of the agreements which range from five to six years.
	The following table details the amount of amortization expense recorded for intangible assets for the three and six months ended June 30, 2014 and 2013 (in thousands):
		Three Months Ended June 30,					Six Months Ended June 30,
		2014			2013		2014		2013
	Referral relationships	$	128		$	116	$	283	$	266
	Non-competition agreements		62			85		149		191
		$	190		$	201	$	432	$	457
	Based on the balance of referral relationships and non-competition agreements as of June 30, 2014, the expected amount to be amortized in 2014 and thereafter by year is as follows (in thousands):
	Referral Relationships			Non Competition Agreements
		Annual			Annual
	Years	Amount		Years	Amount
	2014	535		2014	272
	2015	486		2015	246
	2016	486		2016	185
	2017	486		2017	140
	2018	449		2018	84
	2019	413		2019	19
	2020	413
	2021	413
	2022	364
	2023	257
	2024	137
	2025	49
	2026	11

ACCRUED_EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2014
ACCRUED EXPENSES [Abstract]	'
ACCRUED EXPENSES	'
	8. ACCRUED EXPENSES
	Accrued expenses as of June 30, 2014 and December 31, 2013 consisted of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Salaries and related costs	$	12,373	$	11,686
	Group health insurance claims		2,227		2,023
	Credit balances and overpayments due to patients and payors		1,581		2,371
	Other		3,931		4,545
	Total	$	20,112	$	20,625

NOTES_PAYABLE_AND_CREDIT_AGREE

NOTES PAYABLE AND CREDIT AGREEMENT	6 Months Ended
	Jun. 30, 2014
NOTES PAYABLE AND CREDIT AGREEMENT [Abstract]	'
NOTES PAYABLE AND CREDIT AGREEMENT	'
	9. NOTES PAYABLE AND CREDIT AGREEMENT
	Amounts outstanding under the Credit Agreement and notes payable as of June 30, 2014 and December 31, 2013 consisted of the following (in thousands):
		2014			2013
	Credit Agreement average effective interest rate of 2.5% inclusive of unused fee	$	45,000		$	40,000
	Various notes payable with $850 plus accrued interest due in the next year, interest accrues at 3.25% per annum		1,300			1,475
			46,300			41,475
	Less current portion		(850	)		(825	)
		$	45,450		$	40,650
	Effective December 5, 2013, the Company entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility with a maturity date of November 30, 2018 (“Credit Agreement”). The Credit Agreement is unsecured and has loan covenants, including requirements that the Company comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Credit Agreement may be used for working capital, acquisitions, purchases of the Company’s common stock, dividend payments to the Company’s common shareholders, capital expenditures and other corporate purposes. The pricing grid is based on the Company’s consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.5% to 2.5% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Credit Agreement include an unused commitment fee ranging from 0.1% to 0.25% depending on the Company’s consolidated leverage ratio and the amount of funds outstanding under the Credit Agreement.
	On June 30, 2014, $45.0 million was outstanding on the Credit Agreement resulting in $80.0 million of availability. As of June 30, 2014, the Company was in compliance with all of the covenants thereunder.
	The Company generally enters into various notes payable as a means of financing a portion of its acquisitions. In conjunction with the acquisition in 2014, the Company entered into a note payable in the amount of $400,000, payable in two annual equal installments of $200,000 plus any accrued and unpaid interest. Interest accrues at 3.25% per annum.   In conjunction with the acquisitions in 2013, the Company entered into notes payable in the aggregate amount of $1.3 million, each payable in two annual equal installments totaling $650,000 plus any accrued and unpaid interest. Interest accrues at 3.25% per annum, subject to adjustment.   In conjunction with the acquisitions in 2012, the Company entered into notes payable in the aggregate amount of $350,000, each payable in two annual equal installments totaling $175,000 plus any accrued and unpaid interest. Interest accrues at 3.25% per annum.
	Aggregate annual payments of principal required pursuant to the Credit Agreement and the above notes payable subsequent to June 30, 2014 are as follows (in thousands):
	During the twelve months ended June 30, 2015	$	850
	During the twelve months ended June 30, 2016		450
	During the twelve months ended June 30, 2019		45,000
		$	46,300

COMMON_STOCK

COMMON STOCK	6 Months Ended
	Jun. 30, 2014
COMMON STOCK [Abstract]	'
COMMON STOCK	'
	10. COMMON STOCK
	From September 2001 through December 31, 2008, the Board authorized the Company to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of the Company’s common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of its common stock (“March 2009 Authorization”). In connection with the March 2009 Authorization, the Company amended the Credit Agreement to permit share repurchases of up to $15,000,000. The Company is required to retire shares purchased under the March 2009 Authorization.
	Under the March 2009 Authorization, the Company has purchased a total of 859,499 shares. There is no expiration date for the share repurchase program. The Credit Agreement was further amended to permit the Company to purchase, commencing on October 24, 2012 and at all times thereafter, up to $15,000,000 of its common stock subject to compliance with covenants. There are currently an additional estimated 340,501 shares that may be purchased from time to time in the open market or private transactions depending on price, availability and the Company’s cash position. The Company did not purchase any shares of its common stock during the six months ended June 30, 2014.

BASIS_OF_PRESENTATION_AND_SIGN1

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2014
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Long-Lived Assets	'
	Long-Lived Assets
	Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets. Estimated useful lives for furniture and equipment range from three to eight years and for software purchased from three to seven years. Leasehold improvements are amortized over the shorter of the lease term or estimated useful lives of the assets, which is generally three to five years.
Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of	'
	Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of
	The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Goodwill	'
	Goodwill
	Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital.
	The fair value of goodwill and other intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining our reporting units when performing our annual goodwill impairment test.
	An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two methods: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a put price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2013, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluations in the third quarter of 2013 and 2012 did not yield any impairment charge. During the six months ended June 30, 2014, the Company did not identify any triggering events occurring after the testing date that would impact the impairment testing results obtained.
Non-controlling interests	'
	Non-controlling interests
	The Company recognizes non-controlling interests as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the income statement. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling interest on the deconsolidation date.
	When the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.
	The non-controlling interests that are reflected as redeemable non-controlling interests in the consolidated financial statements consist of those owners who have certain redemption rights that are currently exercisable, and that, if exercised, require that the Company purchase the non-controlling interest of the particular limited partner.  The redeemable non-controlling interests are adjusted to the fair value in the reporting period in which the Company deems it probable that the limited partner will assert the redemption rights and will be adjusted each reporting period thereafter.  The adjustments are charged to additional paid-in capital and are not reflected in the statement of net income.  Although the adjustments are not reflected in the statement of net income, current accounting rules require that the Company reflect the charge in the earnings per share calculation.
	Typically, for acquisitions, the Company agrees to purchase the individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.
Revenue Recognition	'
	Revenue Recognition
	Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience.
	The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in clinic operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.
	Medicare Reimbursement
	The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (“MPFS”). The MPFS rates are automatically updated annually based on a formula, called the sustainable growth rate (“SGR”) formula. The use of the SGR formula would have resulted in calculated automatic reductions in rates in every year since 2002; however, for each year through June 30, 2014, Centers for Medicare & Medicaid Services (“CMS”) or Congress has taken action to prevent the implementation of SGR formula reductions. The Bipartisan Budget Act of 2013 froze the Medicare physician fee schedule rates at 2013 levels through June 30, 2014, averting a scheduled 20.1% cut in the MPFS as a result of the SGR formula that would have taken effect on January 1, 2014. The Protecting Access to Medicare Act of 2014 temporarily blocks this reduction through March 31, 2015 and replaces it with a 0.5% payment increase for services provided through December 31, 2014 and a 0% payment update from January 1, 2015 through March 31, 2015. Automatic reductions in the Medicare physician fee schedule payment rates will commence on April 1, 2015, unless Congress again takes legislative action to prevent the SGR formula reductions from going into effect.
	The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap.  On April 1, 2013, a 2% reduction to Medicare payments was implemented.
	As a result of the Balanced Budget Act of 1997, the formula for determining the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary (i.e., the “Therapy Cap” or “Limit”) was established. Based on the statutory definitions which constrained how the Therapy Cap would be applied, there is one Limit for Physical Therapy and Speech Language Pathology Services combined, and one Limit for Occupational Therapy. Since January 1, 2014, the annual Limit on outpatient therapy services is $1,920 for Physical and Speech Language Pathology Services combined and $1,920 for Occupational Therapy Services.  Historically, these Therapy Caps applied to outpatient therapy services provided in all settings, except for services provided in departments of hospitals. However, the Protecting Access to Medicare Act of 2014, and prior legislation, extended the annual limits on therapy expenses and the manual medical review thresholds to services furnished in hospital outpatient department settings through March 31, 2015. The application of annual limits will no longer apply to hospital outpatient department settings commencing as of March 31, 2015 unless Congress extends it.
	In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual Limit for therapy expenses for therapy services above the annual Limit.  Therapy services above the annual Limit that are medically necessary satisfy an exception to the annual Limit and such claims are payable by the Medicare program. The Protecting Access to Medicare Act of 2014 extended the exceptions process for outpatient therapy caps through March 31, 2015.   Unless Congress extends the exceptions process further, the therapy caps will apply to all outpatient therapy services beginning April 1, 2015, except those services furnished and billed by outpatient hospital departments.  For any claim above the annual Limit, the claim must contain a modifier indicating that the services are medically necessary and justified by appropriate documentation in the medical record.
	Furthermore, under the Middle Class Tax Relief and Job Creation Act of 2012 (“MCTRA”), since October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review to determine whether applicable payment criteria are satisfied. The $3,700 threshold is applied to Physical Therapy and Speech Language Pathology Services; a separate $3,700 threshold is applied to the Occupational Therapy. The Protecting Acces to Medicare Act of 2014 extended through March 31, 2015 the requirement that Medicare perform manual medical review of therapy services beyond the $3,700 threshold.
	CMS adopted a multiple procedure payment reduction (“MPPR”) for therapy services in the final update to the MPFS for calendar year 2011. During 2011, the MPPR applied to all outpatient therapy services paid under Medicare Part B — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (“RVU”) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. In 2011 and 2012, the practice expense component for the second and subsequent therapy service furnished during the same day for the same patient was reduced by 20% in office and other non-institutional settings and by 25% in institutional settings. The American Taxpayer Relief Act of 2012 increased the payment reduction of the practice expense component to 50%, on subsequent therapy procedures in either setting, effective April 1, 2013. In addition, the Middle Class Tax Relief and Job Creation Act of 2012 (“MCTRA”) directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. Since July 1, 2013, therapists have been required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge. Since July 1, 2013, CMS has rejected claims if the required data is not included in the claim.
	The Physician Quality Reporting System, or "PQRS," is a CMS reporting program that uses a combination of incentive payments and payment reductions to promote reporting of quality information by "eligible professionals." Although physical therapists, occupational therapists and qualified speech-language therapists are generally able to participate in the PQRS program, therapy professionals for whose services we bill through our rehab agencies cannot participate because the Medicare claims processing systems currently cannot accommodate institutional providers such as rehab agencies. Eligible professionals, such as those of our therapy professionals for whose services we bill using their individual Medicare provider numbers, who do not satisfactorily report data on quality measures will be subject to a 2% reduction in their Medicare payment in 2016.
	Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. The Company believes that it is in compliance in all material respects with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements as of June 30, 2014. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program.
	Management Contract Revenues
	Management contract revenues are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company’s employees, are recorded when incurred. Management contract revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income.
Contractual Allowances	'
	Contractual Allowances
	Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements for such services by both insurance companies and government sponsored healthcare programs. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company’s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow it to provide the necessary detail and accuracy with its collectibility estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company’s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company’s billing systems may not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues, and hence, its contractual allowance reserves. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, the difference between net revenues and corresponding cash collections has historically generally reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent period’s contractual write-offs on a payor basis shows a less than 1% difference between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at June 30, 2014.
Income Taxes	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.
	The Company recognizes accrued interest expense and penalties associated with unrecognized tax benefits as income tax expense. The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the three and six months ended June 30, 2014 and 2013.
	On September 13, 2013, the U.S. Treasury Department and the I.R.S. issued final regulations that address costs incurred in acquiring, producing, or improving tangible property (the “Tangible Property Regulations”).  The Tangible Property Regulations are generally effective for tax years beginning on or after January 1, 2014, and may be adopted in earlier years.  The Company adopted the tax treatment of expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property as of January 1, 2014.  Historically, the Company has treated the expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property similar for tax and book.  Management does not anticipate the impact of these changes to be material to the Company’s consolidated financial statements.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount of the Company’s revolving line of credit approximates its fair value. The interest rate on the revolving line of credit, which is tied to the Eurodollar Rate, is set at various short-term intervals as detailed in the Credit Agreement (as defined in Note 9).
Segment Reporting	'
	Segment Reporting
	Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.
Use of Estimates	'
	Use of Estimates
	In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.
Self-Insurance Program	'
	Self-Insurance Program
	The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through June 30, 2014.
Restricted Stock	'
	Restricted Stock
	Restricted stock issued to employees and directors is subject to certain conditions, including continued employment or continued service on our Board of Directors (the “Board”), respectively. The transfer restrictions for shares granted to directors lapse in four equal quarterly installments and those to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the service period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.
Reclassifications	'
	Reclassifications
	Prior period amounts have been reclassified to conform to current period presentation due to discontinued operations recognized in 2013.
Recently Issued Accounting Guidance	'
	Recently Issued Accounting Guidance
	In April 2014, the Financial Accounting Standards Board issued changes to reporting discontinued operations and disclosures of disposals of components of an entity. These changes require a disposal of a component to meet a higher threshold in order to be reported as a discontinued operation in an entity's financial statements. The threshold is defined as a strategic shift that has, or will have, a major effect on an entity's operations and financial results such as a disposal of a major geographical area or a major line of business. Additionally, the following two criteria have been removed from consideration of whether a component meets the requirements for discontinued operations presentation: (i) the operations and cash flows of a disposal component have been or will be eliminated from the ongoing operations of an entity as a result of the disposal transaction, and (ii) an entity will not have any significant continuing involvement in the operations of the disposal component after the disposal transaction. Furthermore, equity method investments now may qualify for discontinued operations presentation. These changes also require expanded disclosures for all disposals of components of an entity, whether or not the threshold for reporting as a discontinued operation is met, related to profit or loss information and/or asset and liability information of the component. These changes become effective for the Company on January 1, 2015. Management has determined that the adoption of these changes will not have an immediate impact on the Consolidated Financial Statements.

BASIS_OF_PRESENTATION_AND_SIGN2

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2014
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Schedule of Clinic Acquisition	'
	During the first six months of 2014 and the year ended 2013, the Company acquired the following clinic groups:
			% Interest	Number of
	Acquisition	Date	Acquired	Clinics
		2014
	April 2014 Acquisition	30-Apr	70%	13
		2013
	February 2013 Acquisition	28-Feb	72%	9
	April 2013 Acquisition	30-Apr	50%	5
	May 2013 Acquisition	24-May	80%	5
	December 9, 2013 Acquisition	9-Dec	60%	12
	December 13, 2013 Acquisition	13-Dec	90%	11

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2014
EARNINGS PER SHARE [Abstract]	'
Computations of Basic and Diluted Earnings Per Share	'
	The computations of basic and diluted earnings per share for the Company are as follows (in thousands, except per share data):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Earnings attributable to common shareholders:
	From continuing operations	$	6,432		$	5,079		$	10,660		$	8,930
	From discontinued operations		-			(165	)		-			(295	)
			6,432			4,914			10,660			8,635
	Revaluation of redeemable non-controlling interests, net of tax		(119	)		-			(1,086	)		-
		$	6,313		$	4,914		$	9,574		$	8,635
	Diluted earnings per share attributable to common shareholders:
	From continuing operations	$	0.53		$	0.42		$	0.87		$	0.74
	Basic earnings per share attributable to common shareholders:
	From continuing operations	$	0.53		$	0.42		$	0.88		$	0.74
	Charges to additional-paid-in-capital  - revaluation of redeemable non-controlling interests, net of tax		(0.01	)		-			(0.09	)		-
	From discontinued operations		-			(0.01	)		-			(0.02	)
	Basic	$	0.52		$	0.41		$	0.79		$	0.72
	Diluted earnings per share attributable to common shareholders:
	From continuing operations	$	0.53		$	0.42		$	0.87		$	0.74
	Charges to additional-paid-in-capital - revaluation of redeemable non-controlling interests, net of tax		(0.01	)		-			(0.09	)		-
	From discontinued operations		-			(0.01	)		-			(0.02	)
	Diluted	$	0.52		$	0.41		$	0.78		$	0.72
	Shares used in computation:
	Basic earnings per share - weighted-average shares		12,224			12,089			12,177			12,022
	Effect of dilutive securities - stock options		2			21			7			22
	Denominator for diluted earnings per share - adjusted weighted-average shares		12,226			12,110			12,184			12,044

ACQUISITIONS_OF_BUSINESSES_Tab

ACQUISITIONS OF BUSINESSES (Tables)	6 Months Ended
	Jun. 30, 2014
Schedule of Preliminary Purchase Prices Allocation	'
	The purchase prices for the 2014 acquisitions have been preliminarily allocated as follows (in thousands):
	Cash paid, net of cash acquired	$	10,750
	Seller notes		400
	Total consideration	$	11,150
	Estimated fair value of net tangible assets acquired:
	Total current assets	$	1,203
	Total non-current assets		1,200
	Total liabilities		(374	)
	Net tangible assets acquired		2,029
	Referral relationships		-
	Non-competition agreements		-
	Tradename		-
	Goodwill		13,846
	Fair value of non-controlling interest		(4,725	)
		$	11,150
	The purchase prices for the 2013 acquisitions have been preliminarily allocated as follows (in thousands):
	Cash paid, net of cash acquired	$	46,628
	Seller notes		1,300
	Total consideration	$	47,928
	Estimated fair value of net tangible assets acquired:
	Total current assets	$	3,756
	Total non-current assets		2,283
	Total liabilities		(1,082	)
	Net tangible assets acquired		4,957
	Referral relationships		940
	Non-competition agreements		400
	Tradename		1,500
	Goodwill		50,672
	Fair value of non-controlling interest		(10,541	)
		$	47,928
Schedule of Clinic Acquisition	'
	During the first six months of 2014 and the year ended 2013, the Company acquired the following clinic groups:
				% Interest		Number of
	Acquisition	Date		Acquired		Clinics
		2014
	April 2014 Acquisition	30-Apr		70%		13
		2013
	February 2013 Acquisition	28-Feb		72%		9
	April 2013 Acquisition	30-Apr		50%		5
	May 2013 Acquisition	24-May		80%		5
	December 9, 2013 Acquisition	9-Dec		60%		12
	December 13, 2013 Acquisition	13-Dec		90%		11
Schedule of Unaudited Proforma Net Revenue and Net Income from Continuing Operations	'
	Unaudited proforma net revenue and net income from continuing operations for the Company as if the December 13, 2013 Acquisition occurred as of January 1, 2013 is as follows (in thousands, except per share data):
		Three Months				Six Months
		Ended				Ended
		30-Jun-13				30-Jun-13
	Net revenues	$	69,563			$	135,024
	Net income attributable to common shareholders from continuing operations	$	5,717			$	9,750
	Earnings per share:
	Basic - net income attributable to common shareholders from continuing operations	$	0.47			$	0.81
	Diluted - net income attributable to common shareholders from continuing operations	$	0.47			$	0.81
	Shares used in computation:
	Basic - net income attributable to common shareholders from continuing operations		12,089				12,022
	Diluted - net income attributable to common shareholders from continuing operations		12,110				12,044
Multi Clinic Acquisitions of Physical Therapy [Member]	'
Schedule of Clinic Acquisition	'
	During 2013, the Company completed the following multi-clinic acquisitions of physical therapy practices:
				% Interest				Number of
	Acquisition	Date		Acquired				Clinics
	February 2013 Acquisition	28-Feb			72%			9
	April 2013 Acquisition	30-Apr			50%			5
	May 2013 Acquisition	24-May			80%			5
	December 9, 2013 Acquisition	9-Dec			60%			12
	December 13, 2013 Acquisition	13-Dec			90%			11

ACQUISITIONS_AND_REVALUATIONS_1

ACQUISITIONS AND REVALUATIONS OF NON-CONTROLLING INTERESTS (Tables)	6 Months Ended
	Jun. 30, 2014
ACQUISITIONS AND REVALUATIONS OF NON-CONTROLLING INTERESTS [Abstract]	'
Changes in Carrying Amount of Redeemable Non-Controlling Interest	'
	For the six months ended June 30, 2014, the following table details the changes in the carrying amount of redeemable non-controlling interest:
		Six Months
		Ended
		30-Jun-14
	Beginning balance	$	4,104
	Increase due to revaluation and operating results of redeemable non-controlling interests		1,869
	Purchases of redeemable non-controlling interests		(4,887	)
	Ending balance	$	1,086

DISCONTINUED_OPERATIONS_Tables

DISCONTINUED OPERATIONS (Tables)	6 Months Ended
	Jun. 30, 2014
DISCONTINUED OPERATIONS [Abstract]	'
Schedule of Details of Losses Reported for Physician Services	'
	The following table details the losses from discontinued operations reported for the physician services business:
		Three Months			Six Months
		Ended			Ended
		30-Jun-13			30-Jun-13
	Net revenues	$	355		$	696
	Operating costs		636			1,168
	Gross margin		(281	)		(472	)
	Direct general and administrative expenses less proceeds		94			187
			(375	)		(659	)
	Tax benefit		107			191
	Loss from discontinued operations	$	(268	)	$	(468	)

GOODWILL_Tables

GOODWILL (Tables)	6 Months Ended
	Jun. 30, 2014
GOODWILL [Abstract]	'
Summary of Changes in Carrying Amount of Goodwill	'
	The changes in the carrying amount of goodwill consisted of the following (in thousands):
		Six Months
		Ended
		30-Jun-14
	Beginning balance	$	143,955
	Goodwill acquired during the period		13,846
	Goodwill allocated to specific assets for business acquired in first six months of 2013		(1,680	)
	Goodwill adjustments for purchase price allocation of businesses acquired		86
	Ending balance	$	156,207

INTANGIBLE_ASSETS_NET_Tables

INTANGIBLE ASSETS, NET (Tables)	6 Months Ended
	Jun. 30, 2014
INTANGIBLE ASSETS, NET [Abstract]	'
Intangible Assets, Net	'
	Intangible assets, net as of June 30, 2014 and December 31, 2013 consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Tradenames	$	10,714		$	9,814
	Referral relationships, net of accumulated amortization of $1,865 and $1,582, respectively		4,216			3,959
	Non-competition agreements, net of accumulated amortization of $2,099 and $1,950, respectively		797			706
		$	15,727		$	14,479
Amortization Expenses	'
	The following table details the amount of amortization expense recorded for intangible assets for the three and six months ended June 30, 2014 and 2013 (in thousands):
		Three Months Ended June 30,					Six Months Ended June 30,
		2014			2013		2014		2013
	Referral relationships	$	128		$	116	$	283	$	266
	Non-competition agreements		62			85		149		191
		$	190		$	201	$	432	$	457
Amortization of Referral Relationships and Non-Competition Agreements	'
	Based on the balance of referral relationships and non-competition agreements as of June 30, 2014, the expected amount to be amortized in 2014 and thereafter by year is as follows (in thousands):
	Referral Relationships			Non Competition Agreements
		Annual			Annual
	Years	Amount		Years	Amount
	2014	535		2014	272
	2015	486		2015	246
	2016	486		2016	185
	2017	486		2017	140
	2018	449		2018	84
	2019	413		2019	19
	2020	413
	2021	413
	2022	364
	2023	257
	2024	137
	2025	49
	2026	11

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2014
ACCRUED EXPENSES [Abstract]	'
Summary of Accrued Expenses	'
	Accrued expenses as of June 30, 2014 and December 31, 2013 consisted of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Salaries and related costs	$	12,373	$	11,686
	Group health insurance claims		2,227		2,023
	Credit balances and overpayments due to patients and payors		1,581		2,371
	Other		3,931		4,545
	Total	$	20,112	$	20,625

NOTES_PAYABLE_AND_CREDIT_AGREE1

NOTES PAYABLE AND CREDIT AGREEMENT (Tables)	6 Months Ended
	Jun. 30, 2014
NOTES PAYABLE AND CREDIT AGREEMENT [Abstract]	'
Summary of Credit Agreement and Notes Payable	'
	Amounts outstanding under the Credit Agreement and notes payable as of June 30, 2014 and December 31, 2013 consisted of the following (in thousands):
		2014			2013
	Credit Agreement average effective interest rate of 2.5% inclusive of unused fee	$	45,000		$	40,000
	Various notes payable with $850 plus accrued interest due in the next year, interest accrues at 3.25% per annum		1,300			1,475
			46,300			41,475
	Less current portion		(850	)		(825	)
		$	45,450		$	40,650
Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility	'
	Aggregate annual payments of principal required pursuant to the Credit Agreement and the above notes payable subsequent to June 30, 2014 are as follows (in thousands):
	During the twelve months ended June 30, 2015	$	850
	During the twelve months ended June 30, 2016		450
	During the twelve months ended June 30, 2019		45,000
		$	46,300

BASIS_OF_PRESENTATION_AND_SIGN3

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
	Clinic		Clinic
	State		State
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Percentage of general partnership interest owned (in hundredths)	'	'	1.00%	'
Percentage of limited partnership interest owned (in hundredths)	'	'	64.00%	'
Number of clinics operated	486	'	486	'
Number of states where clinics are operated	43	'	43	'
Percentage of reduction prevented in Medicare Fee rate (in hundredths)	'	'	20.10%	'
Medicare service fees, description	'	'	'The Protecting Access to Medicare Act of 2014 temporarily blocks this reduction through March 31, 2015 and replaces it with a 0.5% payment increase for services provided through December 31, 2014 and a 0% payment update from January 1, 2015 through March 31, 2015	'
Federal debt ceiling in connection with deficit reductions	'	'	'10 years	'
Reductions in federal spending	'	'	$1,200,000,000,000	'
Medicare spending cut percentage (in hundredths)	'	'	2.00%	'
Expected reduction in Medicare spending percentage (in hundredths)	2.00%	'	2.00%	'
Combined physical therapy/speech language pathology expenses	'	'	3,700	'
Percentage of practice expense component (in hundredths)	'	'	100.00%	'
Percentage reduction for service (in hundredths)	'	'	20.00%	'
Percentage reduction for service in institutional settings (in hundredths)	'	'	25.00%	'
Percentage of increased payment reduction (in hundredths)	'	'	50.00%	'
Difference between net revenues and corresponding cash collections, approximately of net revenues (in hundredths)	'	'	1.00%	'
Maximum difference between actual aggregate contractual reserve and estimated contractual allowance reserve (in hundredths)	'	'	1.00%	'
Minimum difference between actual aggregate contractual reserve and estimated contractual allowance reserve (in hundredths)	'	'	1.00%	'
Minimum percentage of fair value reporting unit less than carrying amount (in hundredths)	'	'	50.00%	'
Unrecognized tax benefit	0	0	0	0
Accrued interest and penalties associated with any unrecognized tax benefits	0	0	0	0
Interest expense recognized	0	0	0	0
Shares granted to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant	'	'	'Shares granted to directors lapse in four equal quarterly installments and those to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant	'
Year 2016 [Member]	'	'	'	'
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Expected reduction in Medicare spending percentage (in hundredths)	2.00%	'	2.00%	'
Through December 31, 2014 [Member]	'	'	'	'
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Percentage of increase in payment for service (in hundredths)	'	'	0.50%	'
January 1, 2015 through March 31, 2015 [Member]	'	'	'	'
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Percentage of medicare payment (in hundredths)	'	'	0.00%	'
Minimum [Member] | Furniture & equipment [Member]	'	'	'	'
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Estimated useful lives	'	'	'3 years	'
Minimum [Member] | Computer Software, Intangible Asset [Member]	'	'	'	'
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Estimated useful lives	'	'	'3 years	'
Minimum [Member] | Leasehold Improvements [Member]	'	'	'	'
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Estimated useful lives	'	'	'3 years	'
Maximum [Member]	'	'	'	'
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Annual limit on physical therapy and speech language pathology services	'	'	1,920	'
Annual limit occupational therapy services	'	'	$1,920	'
Maximum [Member] | Furniture & equipment [Member]	'	'	'	'
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Estimated useful lives	'	'	'8 years	'
Maximum [Member] | Computer Software, Intangible Asset [Member]	'	'	'	'
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Estimated useful lives	'	'	'7 years	'
Maximum [Member] | Leasehold Improvements [Member]	'	'	'	'
Depreciation Amortization Impairment [Line Items]	'	'	'	'
Estimated useful lives	'	'	'5 years	'

BASIS_OF_PRESENTATION_AND_SIGN4

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Clinic Acquisition (Details)	Sep. 16, 2013	Jun. 01, 2013	Feb. 01, 2013	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
				April 2014 Acquisition [Member]	February 2013 Acquisition [Member]	April 2013 Acquisition [Member]	May 2013 Acquisition [Member]	December 9, 2013 Acquisition [Member]	December 13, 2013 Acquisition [Member]
				Clinic	Clinic	Clinic	Clinic	Clinic	Clinic
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Acquisition date	'	'	'	30-Apr-14	28-Feb-13	30-Apr-13	24-May-13	9-Dec-13	13-Dec-13
Percentage of interest acquired (in hundredths)	100.00%	100.00%	100.00%	70.00%	72.00%	50.00%	80.00%	60.00%	90.00%
Number of Clinics	'	'	'	13	9	5	5	12	11

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings attributable to common shareholders [Abstract]	'	'	'	'
From continuing operations	$6,432	$5,079	$10,660	$8,930
From discontinued operations	0	-165	0	-295
Net income attributable to common shareholders	6,432	4,914	10,660	8,635
Revaluation of redeemable non-controlling interests, net of tax	-119	0	-1,086	0
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest, Total	$6,313	$4,914	$9,574	$8,635
Basic earnings per share attributable to common shareholders [Abstract]	'	'	'	'
From continuing operations (in dollars per share)	$0.53	$0.42	$0.88	$0.74
Charges to additional-paid-in-capital - revaluation of redeemable non-controlling interests, net of tax (in dollars per share)	($0.01)	$0	($0.09)	$0
From discontinued operations (in dollars per share)	$0	($0.01)	$0	($0.02)
Basic (in dollars per share)	$0.52	$0.41	$0.79	$0.72
Diluted earnings per share attributable to common shareholders [Abstract]	'	'	'	'
From continuing operations (in dollars per share)	$0.53	$0.42	$0.87	$0.74
Charges to additional-paid-in-capital - revaluation of redeemable non-controlling interests, net of tax (in dollars per share)	($0.01)	$0	($0.09)	$0
From discontinued operations (in dollars per share)	$0	($0.01)	$0	($0.02)
Diluted (in dollars per share)	$0.52	$0.41	$0.78	$0.72
Shares used in computation [Abstract]	'	'	'	'
Basic earnings per share - weighted-average shares (in shares)	12,224	12,089	12,177	12,022
Effect of dilutive securities - stock options (in shares)	2	21	7	22
Denominator for diluted earnings per share - adjusted weighted-average shares (in shares)	12,226	12,110	12,184	12,044

ACQUISITIONS_OF_BUSINESSES_Add

ACQUISITIONS OF BUSINESSES - Additional Information (Details) (USD $)	0 Months Ended			6 Months Ended	12 Months Ended
	Sep. 16, 2013	Jun. 01, 2013	Feb. 01, 2013	Jun. 30, 2014	Dec. 31, 2013	Sep. 16, 2013	Jun. 01, 2013	Feb. 01, 2013
					Clinic
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Number of multi-clinic acquisitions	'	'	'	'	5	'	'	'
Percentage of interest acquired (in hundredths)	'	'	'	'	'	100.00%	100.00%	100.00%
Business acquisition cost of acquired entity debt issued	'	'	'	$400,000	$1,300,000	'	'	'
Business acquisition, cost of acquired entity	130,000	95,000	5,000	11,150,000	47,928,000	'	'	'
February 2014 [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquisition cost payable in two principal installments including accrued interest	'	'	'	'	200,000	'	'	'
February 2015 [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquisition cost payable in two principal installments including accrued interest	'	'	'	'	200,000	'	'	'
April 2014 [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquisition cost payable in two principal installments including accrued interest	'	'	'	'	100,000	'	'	'
April 2015 [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquisition cost payable in two principal installments including accrued interest	'	'	'	200,000	100,000	'	'	'
April 2016 [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquisition cost payable in two principal installments including accrued interest	'	'	'	200,000	'	'	'	'
May 2014 [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquisition cost payable in two principal installments including accrued interest	'	'	'	'	100,000	'	'	'
May 2015 [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquisition cost payable in two principal installments including accrued interest	'	'	'	'	100,000	'	'	'
December 2014 [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquisition cost payable in two principal installments including accrued interest	'	'	'	'	250,000	'	'	'
December 2015 [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquisition cost payable in two principal installments including accrued interest	'	'	'	'	250,000	'	'	'
Acquisition Of Thirteen Clinic Practices [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Number of clinic practices acquired	'	'	'	13	'	'	'	'
Cash paid for acquisition of interest in clinic	'	'	'	10,625,000	'	'	'	'
Percentage of interest acquired (in hundredths)	'	'	'	70.00%	'	'	'	'
Business acquisition number of installments to payment of purchase consideration	'	'	'	2	'	'	'	'
Acquisition Of Two Clinic Practices [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Number of clinic practices acquired	'	'	'	2	'	'	'	'
Cash paid for acquisition of interest in clinic	'	'	'	125,000	'	'	'	'
Acquisition Of Clinics On Separate Transactions[Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Number of clinic practices acquired	'	'	'	'	3	'	'	'
February 2013 Acquisition [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Number of clinic practices acquired	'	'	'	'	9	'	'	'
Cash paid for acquisition of interest in clinic	'	'	'	'	4,300,000	'	'	'
Percentage of interest acquired (in hundredths)	'	'	'	'	72.00%	'	'	'
Business acquisition cost of acquired entity debt issued	'	'	'	'	400,000	'	'	'
Business acquisition number of installments to payment of purchase consideration	'	'	'	'	2	'	'	'
April 2013 Acquisition [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Number of clinic practices acquired	'	'	'	'	5	'	'	'
Cash paid for acquisition of interest in clinic	'	'	'	'	2,400,000	'	'	'
Percentage of interest acquired (in hundredths)	'	'	'	'	50.00%	'	'	'
Business acquisition cost of acquired entity debt issued	'	'	'	'	200,000	'	'	'
Business acquisition number of installments to payment of purchase consideration	'	'	'	'	2	'	'	'
May 2013 Acquisition [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Number of clinic practices acquired	'	'	'	'	5	'	'	'
Cash paid for acquisition of interest in clinic	'	'	'	'	3,600,000	'	'	'
Percentage of interest acquired (in hundredths)	'	'	'	'	80.00%	'	'	'
Business acquisition cost of acquired entity debt issued	'	'	'	'	200,000	'	'	'
Business acquisition number of installments to payment of purchase consideration	'	'	'	'	2	'	'	'
December 9, 2013 Acquisition [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Number of clinic practices acquired	'	'	'	'	12	'	'	'
Cash paid for acquisition of interest in clinic	'	'	'	'	1,700,000	'	'	'
Percentage of interest acquired (in hundredths)	'	'	'	'	60.00%	'	'	'
December 13, 2013 Acquisition [Member]	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Number of clinic practices acquired	'	'	'	'	11	'	'	'
Cash paid for acquisition of interest in clinic	'	'	'	'	35,500,000	'	'	'
Percentage of interest acquired (in hundredths)	'	'	'	'	90.00%	'	'	'
Business acquisition cost of acquired entity debt issued	'	'	'	'	$500,000	'	'	'
Business acquisition number of installments to payment of purchase consideration	'	'	'	'	2	'	'	'

ACQUISITIONS_OF_BUSINESSES_Sch

ACQUISITIONS OF BUSINESSES - Schedule of Preliminary Purchase Price Allocation (Details) (USD $)	0 Months Ended			6 Months Ended		12 Months Ended
	Sep. 16, 2013	Jun. 01, 2013	Feb. 01, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
ACQUISITIONS OF BUSINESSES [Abstract]	'	'	'	'	'	'
Cash paid, net of cash acquired	'	'	'	$10,750,000	$9,998,000	$46,628,000
Seller notes	'	'	'	400,000	'	1,300,000
Total consideration	130,000	95,000	5,000	11,150,000	'	47,928,000
Estimated fair value of net tangible assets acquired [Abstract]	'	'	'	'	'	'
Total current assets	'	'	'	1,203,000	'	3,756,000
Total non-current assets	'	'	'	1,200,000	'	2,283,000
Total liabilities	'	'	'	-374,000	'	-1,082,000
Net tangible assets acquired	'	'	'	2,029,000	'	4,957,000
Referral relationships	'	'	'	0	'	940,000
Non-competition agreements	'	'	'	0	'	400,000
Tradename	'	'	'	0	'	1,500,000
Goodwill	'	'	'	13,846,000	'	50,672,000
Fair value of non-controlling interest	'	'	'	-4,725,000	'	-10,541,000
Total consideration	$130,000	$95,000	$5,000	$11,150,000	'	$47,928,000

ACQUISITIONS_OF_BUSINESSES_Sch1

ACQUISITIONS OF BUSINESSES - Schedule of Multi Clinic Acquisition (Details)	Sep. 16, 2013	Jun. 01, 2013	Feb. 01, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
				February 2013 Acquisition [Member]	April 2013 Acquisition [Member]	May 2013 Acquisition [Member]	December 9, 2013 Acquisition [Member]	December 13, 2013 Acquisition [Member]
				Clinic	Clinic	Clinic	Clinic	Clinic
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquisition date	'	'	'	28-Feb-13	30-Apr-13	24-May-13	9-Dec-13	13-Dec-13
Percentage of interest acquired (in hundredths)	100.00%	100.00%	100.00%	72.00%	50.00%	80.00%	60.00%	90.00%
Number of Clinics	'	'	'	9	5	5	12	11

ACQUISITIONS_OF_BUSINESSES_Una

ACQUISITIONS OF BUSINESSES - Unaudited Proforma Net Revenue and Net Income from Continuing Operations (Details) (USD $)	3 Months Ended	6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2013
ACQUISITIONS OF BUSINESSES [Abstract]	'	'
Net revenues	$69,563	$135,024
Net income attributable to common shareholders from continuing operations	$5,717	$9,750
Earnings per share [Abstract]	'	'
Basic - net income attributable to common shareholders from continuing operations (in dollars per share)	$0.47	$0.81
Diluted - net income attributable to common shareholders from continuing operations (in dollars per share)	$0.47	$0.81
Shares used in computation [Abstract]	'	'
Basic - net income attributable to common shareholders from continuing operations (in shares)	12,089	12,022
Diluted - net income attributable to common shareholders from continuing operations (in shares)	12,110	12,044

ACQUISITIONS_AND_REVALUATIONS_2

ACQUISITIONS AND REVALUATIONS OF NON-CONTROLLING INTERESTS - Additional Information (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Sep. 16, 2013	Jun. 01, 2013	Feb. 01, 2013
	Partnership
Business Acquisition [Line Items]	'	'	'	'
Number of separate transactions to purchase partnership interest	4	'	'	'
Number of partnership in which interest acquired	2	'	'	'
Purchase price for additional non controlling interest	$4.90	'	'	'
Book value of purchase price	3	'	'	'
Remaining purchase price	1.9	'	'	'
Future tax benefits	$0.80	'	'	'
Percentage of interest acquired (in hundredths)	'	100.00%	100.00%	100.00%
Minimum [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Percentage of interest acquired (in hundredths)	10.00%	'	'	'
Maximum [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Percentage of interest acquired (in hundredths)	35.00%	'	'	'

ACQUISITIONS_AND_REVALUATIONS_3

ACQUISITIONS AND REVALUATIONS OF NON-CONTROLLING INTERESTS - Changes in Carrying Amount of Redeemable Non-Controlling Interest (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
ACQUISITIONS AND REVALUATIONS OF NON-CONTROLLING INTERESTS [Abstract]	'
Beginning balance	$4,104
Increase due to revaluation and operating results of redeemable non-controlling interests	1,869
Purchases of redeemable non-controlling interests	-4,887
Ending balance	$1,086

DISCONTINUED_OPERATIONS_Additi

DISCONTINUED OPERATIONS - Additional Information (Details)	1 Months Ended
	Aug. 31, 2013	Dec. 31, 2012
	Facility	Facility
DISCONTINUED OPERATIONS [Abstract]	'	'
Facilities previously closed	1	1

DISCONTINUED_OPERATIONS_Schedu

DISCONTINUED OPERATIONS - Schedule of Details of Losses Reported for Physician Services (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]	'	'	'	'
Loss from discontinued operations	$0	($268)	$0	($468)
Physician Services [Member]	'	'	'	'
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]	'	'	'	'
Net revenues	'	355	'	696
Operating costs	'	636	'	1,168
Gross margin	'	-281	'	-472
Direct general and administrative expenses less proceeds	'	94	'	187
Loss from discontinued operations, before tax	'	-375	'	-659
Tax benefit	'	107	'	191
Loss from discontinued operations	'	($268)	'	($468)

GOODWILL_Details

GOODWILL (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Goodwill [Roll Forward]	'
Beginning balance	$143,955
Goodwill acquired during the period	13,846
Goodwill allocated to specific assets for business acquired in first six months of 2013	-1,680
Goodwill adjustments for purchase price allocation of businesses acquired	86
Ending balance	$156,207

INTANGIBLE_ASSETS_NET_Intangib

INTANGIBLE ASSETS, NET - Intangible Assets, Net (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite Lived Intangible Assets [Line Items]	'	'
Total	$15,727	$14,479
Tradenames [Member]	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Total	10,714	9,814
Referral relationships [Member]	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Total	4,216	3,959
Accumulated amortization	1,865	1,582
Non-competition agreements [Member]	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Total	797	706
Accumulated amortization	$2,099	$1,950

INTANGIBLE_ASSETS_NET_Addition

INTANGIBLE ASSETS, NET - Additional Information (Details)	6 Months Ended
	Jun. 30, 2014
Referral relationships [Member] | Minimum [Member]	'
Finite Lived Intangible Assets [Line Items]	'
Estimated useful life	'6 years
Referral relationships [Member] | Maximum [Member]	'
Finite Lived Intangible Assets [Line Items]	'
Estimated useful life	'16 years
Non-competition agreements [Member] | Minimum [Member]	'
Finite Lived Intangible Assets [Line Items]	'
Estimated useful life	'5 years
Non-competition agreements [Member] | Maximum [Member]	'
Finite Lived Intangible Assets [Line Items]	'
Estimated useful life	'6 years

INTANGIBLE_ASSETS_NET_Amortiza

INTANGIBLE ASSETS, NET - Amortization Expenses (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Finite Lived Intangible Assets [Line Items]	'	'	'	'
Total amortization expenses	$190	$201	$432	$457
Referral relationships [Member]	'	'	'	'
Finite Lived Intangible Assets [Line Items]	'	'	'	'
Total amortization expenses	128	116	283	266
Non-competition agreements [Member]	'	'	'	'
Finite Lived Intangible Assets [Line Items]	'	'	'	'
Total amortization expenses	$62	$85	$149	$191

INTANGIBLE_ASSETS_NET_Amortiza1

INTANGIBLE ASSETS, NET - Amortization of Referral Relationships and Non-Competition Agreements (Details) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Referral relationships [Member]	'
Finite Lived Intangible Assets [Line Items]	'
2014	$535
2015	486
2016	486
2017	486
2018	449
2019	413
2020	413
2021	413
2022	364
2023	257
2024	137
2025	49
2026	11
Non-competition agreements [Member]	'
Finite Lived Intangible Assets [Line Items]	'
2014	272
2015	246
2016	185
2017	140
2018	84
2019	$19

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Salaries and related costs	$12,373	$11,686
Group health insurance claims	2,227	2,023
Credit balances and overpayments due to patients and payors	1,581	2,371
Other	3,931	4,545
Total	$20,112	$20,625

NOTES_PAYABLE_AND_CREDIT_AGREE2

NOTES PAYABLE AND CREDIT AGREEMENT - Summary of Credit Agreement and Notes Payable (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Payments/Long term debt, Total	$46,300	$41,475
Less current portion	-850	-825
Long term portion	45,450	40,650
Credit Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Payments/Long term debt, Total	45,000	40,000
Average effective interest rate (in hundredths)	2.50%	'
3.25 % notes payable due in next year [Member]	'	'
Debt Instrument [Line Items]	'	'
Payments/Long term debt, Total	1,300	1,475
Annual installments	$850	'
Percentage of interest accrued (in hundredths)	3.25%	'

NOTES_PAYABLE_AND_CREDIT_AGREE3

NOTES PAYABLE AND CREDIT AGREEMENT - Additional Information (Details) (USD $)	1 Months Ended			6 Months Ended	12 Months Ended		6 Months Ended
	Dec. 05, 2013	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Dec. 05, 2013
				Notes Payable, Other Payables [Member]	Notes Payable, Other Payables [Member]	Notes Payable, Other Payables [Member]	Minimum [Member]	Maximum [Member]	Revolving credit agreement average effective interest rate of 3.0% inclusive of unused fee [Member]	Revolving credit agreement average effective interest rate of 3.0% inclusive of unused fee [Member]
				Installment	Installment	Installment
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'
Revolving credit facility commitment	'	'	'	'	'	'	'	'	'	$125,000,000
Maturity Date	30-Nov-18	'	'	'	'	'	'	'	'	'
Spread on Libor variable rate (in hundredths)	'	'	'	'	'	'	1.50%	2.50%	'	'
Spread on base variable rate (in hundredths)	'	'	'	'	'	'	0.10%	1.00%	'	'
Percentage of unused commitment fee (in hundredths)	'	'	'	'	'	'	0.10%	0.25%	'	'
Revolving credit outstanding	'	46,300,000	41,475,000	'	'	'	'	'	45,000,000	'
Remaining revolving credit outstanding	'	'	'	'	'	'	'	'	80,000,000	'
Aggregate amount of Notes Payable	'	'	'	400,000	1,300,000	350,000	'	'	'	'
Aggregate principal installments	'	'	'	$200,000	$650,000	$175,000	'	'	'	'
Average effective interest rate (in hundredths)	'	'	'	3.25%	3.25%	3.25%	'	'	'	'
Business Acquisition Purchase Price Allocation Notes Payable Number Of Installment	'	'	'	2	2	2	'	'	'	'

NOTES_PAYABLE_AND_CREDIT_AGREE4

NOTES PAYABLE AND CREDIT AGREEMENT - Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Long Term Debt By Maturity [Abstract]	'	'
During the twelve months ended June 30, 2015	$850	'
During the twelve months ended June 30, 2016	450	'
During the twelve months ended June 30, 2019	45,000	'
Payments/Long term debt, Total	$46,300	$41,475

COMMON_STOCK_Details

COMMON STOCK (Details) (USD $)	0 Months Ended	1 Months Ended	6 Months Ended
	Mar. 31, 2009	Mar. 31, 2009	Jun. 30, 2014	Dec. 31, 2008
Statement Of Partners Capital [Abstract]	'	'	'	'
Common stock authorized by the Board of Directors (in shares)	'	'	'	2,250,000
Maximum percentage of repurchase of common stock (in hundredths)	'	10.00%	'	'
Repurchase of common stock (in shares)	1,200,000	859,499	0	'
Bank credit agreement to permit share repurchases of common stock	'	$15,000,000	'	'
Total purchased shares (in shares)	1,200,000	859,499	0	'
Additional estimated shares (in shares)	'	340,501	'	'